Informations générales (source: ClinicalTrials.gov)
Evaluation of Vascular Toxicity of Immune Checkpoint Inhibitors (Nivolumab, Pembrolizumab, Atezolizumab) in Patients Head and Neck or Lung Cancer
Interventional
N/A
Centre Henri Becquerel (Voir sur ClinicalTrials)
décembre 2022
décembre 2025
22 décembre 2025
Since the introduction of immune checkpoint ihibitors (ICIs) in cancer treatment,
numerous studies have investigated different patient profiles to identify those who
benefit from this class of drugs. Currently, hundreds of studies are being conducted with
the aim of increasing the benefit of these therapies by combining ICIs with other
treatments: immunomodulators, cytotoxics, targeted therapies, including cancer vaccines,
which are peptides or RNA injected to trigger or increase a specific immune response
against the tumor. Other approaches exist, such as oncology-specific "basket" studies, to
focus on a genetic mutation independently of tumor location and determine whether a drug
could treat the same genetic mutation found in several different locations. To date, ICIs
are part of standard management in the US for patients with several diseases: advanced
melanoma, NSCLC, Merkel cell carcinoma, head and neck squamous cell carcinoma, urothelial
and renal cell carcinoma, cancers characterized by microsatellite instability, refractory
Hodgkin's lymphoma, hepatocellular carcinoma, gastric cancer. In addition, trials are
underway to investigate the benefit of ICIs in other locations.
Thus, taking into account the growing importance of ICIs in the oncological therapeutic
strategy and the large number of patients treated, a better understanding of the vascular
impact of these drugs is necessary.
Etablissements
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Centre Henri Becquerel - 76000 - Rouen - France | Nathalie Olympios, MD | Contact (sur clinicalTrials) | |||
| CHU Rouen - 76000 - Rouen - France | Florian Guisier, MD, PhD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Signed informed consent.
- Patient over 18 years of age
- Patient with lung or head and neck cancer who should be treated with ICI as a single
agent according to the market indications, decision taken during a multidisciplinary
consultation meeting
- WHO 0 or 1
- Patient affiliated to or benefiting from a social protection scheme.
- Signed informed consent.
- Patient over 18 years of age
- Patient with lung or head and neck cancer who should be treated with ICI as a single
agent according to the market indications, decision taken during a multidisciplinary
consultation meeting
- WHO 0 or 1
- Patient affiliated to or benefiting from a social protection scheme.
- Indication for combined anti-PD-1 and chemotherapy (for patients with lung cancer)
- History of radiotherapy treatment
- History of chemotherapy or targeted therapy within the last 3 weeks
- Bilateral vascular carotid murmur
- Absence of sinus rhythm
- Presence of a pacemaker with permanent electrical stimulation
- Absence of peripheral carotid and/or femoral pulses on both sides
- Contraindication to the prescription of an ICI
- Patient deprived of liberty by an administrative or judicial decision or patient
placed under court protection, guardianship or curatorship
- Pregnant or breastfeeding woman